Pfizer

PfizerAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.

www.pfizer.com

Pfizer RSS Channel

Display # 
Title Published Date
Pfizer receives World Health Organization prequalification for multi-dose vial presentation of Prevenar 13® 19 July 2016
Merck and Pfizer initiate Phase III trial to evaluate Avelumab as first-line treatment for ovarian cancer 07 July 2016
Pfizer completes acquisition of Anacor 24 June 2016
Help Pfizer change the future of healthy aging 21 June 2016
Pfizer presents promising data from next generation ALK/ROS1 inhibitor in advanced non-small cell lung cancer 06 June 2016
Merck and Pfizer to present Avelumab data in seven different cancers at ASCO annual meeting 19 May 2016
Pfizer awards more than $1 million in metastatic breast cancer research funding 13 May 2016
Pfizer reports first-quarter 2016 results 03 May 2016
Pfizer announces termination of proposed combination with Allergan 07 April 2016
Bristol-Myers Squibb and Pfizer announce global real-world data program and present new analyses of Eliquis (apixaban) 30 March 2016
Pfizer celebrates a year of achievements in 2015 annual review 16 March 2016
Pfizer commences $5 billion accelerated share repurchase 11 March 2016
Merck, Pfizer and Verastem announce combination trial of avelumab and VS-6063 in ovarian cancer 04 March 2016
Pfizer names executive leadership team for combined organization upon close of proposed Allergan transaction 08 February 2016
Bristol-Myers Squibb and Pfizer sign collaboration with Portola Pharmaceuticals 02 February 2016
Pfizer expands R&D equity investment strategy to access early-stage scientific innovations 13 January 2016
Merck KGaA, Darmstadt, Germany, Pfizer and Syndax announce collaboration to evaluate combination of Avelumab and Entinostat in ovarian cancer 04 January 2016
Global partners announce donation of 500 millionth dose of azithromycin 17 November 2015
Pfizer expands its patient assistance program 10 November 2015
Pfizer completes acquisition of Nimenrix and Mencevax from GlaxoSmithKline 06 October 2015

Most Popular Now

New antibiotic Zavicefta approved i…

AstraZeneca today announced that the European Commission (EC) has granted marketing authorisation for Zavicefta (ceftazidime-avibactam, previously known as CAZ AVI), a ne...

Read more

Novo Nordisk and Aarhus University …

Novo Nordisk and Aarhus University's Science and Technology faculty today signed a collaboration agreement to strengthen protein technology research and development. Unde...

Read more

AstraZeneca enters licensing agreem…

AstraZeneca today announced that it has entered into agreements that support its strategic focus on three main therapy areas; Respiratory, Inflammation and Autoimmunity, ...

Read more

Novartis adds bispecific antibodies…

Today Novartis announced that it has entered into a collaboration and licensing agreement with Xencor for the development of bispecific antibodies for treating cancer. Th...

Read more

Bristol-Myers Squibb and PsiOxus Th…

Bristol-Myers Squibb Company (NYSE: BMY) and PsiOxus Therapeutics, Ltd. (PsiOxus) today announced an exclusive clinical collaboration agreement to evaluate the safety, to...

Read more

Bristol-Myers Squibb acquires Cormo…

Bristol-Myers Squibb Company (NYSE:BMY) and Cormorant Pharmaceuticals announced today that Bristol-Myers Squibb has acquired all of the outstanding capital stock of Cormo...

Read more

Sanofi Pasteur signs research agree…

Sanofi and its vaccines global business unit Sanofi Pasteur announced today a Cooperative Research and Development Agreement with the Walter Reed Army Institute of Resear...

Read more

Merck and Pfizer initiate Phase III…

Merck KGaA, Darmstadt, Germany, and Pfizer (NYSE: PFE) have announced the initiation of a Phase III study, JAVELIN Ovarian 100, to evaluate the efficacy and safety of ave...

Read more

FDA advances Precision Medicine Ini…

In support of the President’s Precision Medicine Initiative, the U.S. Food and Drug Administration has issued two draft guidances that, when finalized, will provide a fle...

Read more

Merck commits €1.5 million to the G…

Merck, a leading science and technology company, today announced it would continue to support the advancement of medical science in the field of fertility through the Gra...

Read more

Laboratory drug trials could lead t…

A new drug with the potential to reverse or slow the development of asthma is being tested by researchers at The University of Queensland. Developed by international phar...

Read more

Twisting and turning to target anti…

Researchers are getting closer to understanding how some natural antibiotics work so they can develop drugs that mimic them. A recent review commissioned by the British g...

Read more

Digest World Pharma Newsletter

Subscribe to our weekly Digest World Pharma Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]

© World Pharma News 2006 - 2016